Skip to main content

Table 1 Immunisation schedule

From: Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model

Group

Animal numbers

Vaccine

Schedule (weeks)

Challenge virus

A

A71, A75, A76, A78

W61D rgp120+ AS02A

1, 4, 12, 20, 28, 36, 44, 86

SHIVsbga

B

A72, A73, A74, A77

W61D rgp120+ AS02A

1, 4, 12, 20, 28, 36, 44, 92

SHIVSF33b

C

B234-B237

AS02A

 

SHIVsbgc

D

B238-B241

AS02A

 

SHIVSF33d

E

C37-C40

Serum transfer

 

SHIVsbge

F

C41-C44

None

 

SHIVsbgf

G

G19; G21

W61D rgp120+ AS02A

1, 4, 8

None

  1. a = 10 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
  2. b = 50 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
  3. c = 10MID50 challenge dose contemporaneous with group A.
  4. d = 50MID50 challenge dose contemporaneous with group B.
  5. e = 50MID50 challenge dose given 24 hours following serum transfer.
  6. f = 50MID50 contemporaneous with group F.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us